[{"id":"a3182ec5-ccb1-442e-a4cc-96f753025ed6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05705505","created_at":"2023-01-30T15:59:40.879Z","updated_at":"2024-07-02T16:35:26.447Z","phase":"Phase 1/2","brief_title":"Study of Narazaciclib (ON 123300) Plus Letrozole in Endometrial Cancer and Other Gynecologic Malignancies","source_id_and_acronym":"NCT05705505","lead_sponsor":"Onconova Therapeutics, Inc.","biomarkers":" PGR","pipe":" | ","alterations":" MSI-H/dMMR","tags":["PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e letrozole • narazaciclib (HX301)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 03/29/2023","start_date":" 03/29/2023","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2023-12-12"},{"id":"ac40f894-1232-45a9-9ca4-ea12e9ccf046","acronym":"","url":"https://clinicaltrials.gov/study/NCT05731934","created_at":"2023-02-16T15:00:44.591Z","updated_at":"2024-07-02T16:35:36.101Z","phase":"Phase 1","brief_title":"The Tolerability and Pharmacokinetics of HX301 Monolactate Capsules in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05731934","lead_sponsor":"Hangzhou Hanx Biopharmaceuticals, Ltd.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e narazaciclib (HX301)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 09/15/2020","start_date":" 09/15/2020","primary_txt":" Primary completion: 12/30/2023","primary_completion_date":" 12/30/2023","study_txt":" Completion: 03/28/2024","study_completion_date":" 03/28/2024","last_update_posted":"2023-09-22"}]